Therapeutic Efficacy Analysis of Allogeneic Peripheral Blood Hematopoietic Stem Cell Transplantation for 14 Adult Patients with T Lymphoblastic Lymphoma

• Published in: Zhongguo shi yan xue ye xue za zhi Vol. 24; no. 2; p. 433
• Main Authors: Wei, Hua-Ping, Zhao, Xiao-Li, Huang, Wen-Rong, Bo, Jian, Li, Hong-Hua, Zhao, Yu, Zhu, Hai-Yan, Jin, Yu, Yuan, Lei, Wang, Li, Gu, Zhen-Yang, Yang, Nan, Wang, Fei-Yan, Wang, Quan-Shun, Liu, Dai-Hong, Yu, Li, Gao, Chun-Ji
• Format: Journal Article
• Language: Chinese
• Published: China 01.04.2016
• Subjects: Adult; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - therapy; Retrospective Studies; Survival Rate
• ISSN: 1009-2137
• DOI: 10.7534/j.issn.1009-2137.2016.02.023

To investigate the therapeutic efficacy of allogeneic peripheral blood hematopoietic stem cell transpdantation (allo-HSCT) for T lymphoblastic lymphoma (T-LBL). The clinical data of 14 adult patients with T-LBL treated with allo-HSCT were collected, the hematopoietic reconstruction, survival and relapse, as well as overall survival (OS) rate, event-free survival (EFS) rate of 1, 3 and 5 years were analysed retrospectively. All the patients were engrafted with neutrophil successfully, the median time of absolute neutrophil count >0.5 × 10(9)/L was 13 (10-19) d; 13 patients were engrafted with platelets successfully, the median time of Plt count >20 × 10(9)/L was 17 (12-62) days. The acute GVHD occurred in 6 patients, but among them only 1 case with 3 grade of aGVHD; out of 14 patients, 5 developed chronic GVHD. The transplant-related mortality at 100 days was 7.1% (1/14), mainly from coronary heart disease and pulmonary infection. The median follow-up time was 26.5 months, the estimated 1, 3 and 5 year OS rate